Jessica Fye
Stock Analyst at JP Morgan
(3.81)
# 590
Out of 4,842 analysts
184
Total ratings
51.3%
Success rate
7.16%
Average return
Main Sectors:
Stocks Rated by Jessica Fye
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRNA Moderna | Maintains: Underweight | $33 → $26 | $26.05 | -0.19% | 13 | May 22, 2025 | |
| BNTX BioNTech SE | Maintains: Neutral | $120 → $116 | $97.53 | +18.94% | 11 | May 22, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $512 → $515 | $445.10 | +15.70% | 8 | May 6, 2025 | |
| BCRX BioCryst Pharmaceuticals | Maintains: Overweight | $10 → $13 | $10.56 | +23.11% | 6 | May 6, 2025 | |
| ASND Ascendis Pharma | Maintains: Overweight | $200 → $245 | $159.41 | +53.69% | 11 | May 2, 2025 | |
| UTHR United Therapeutics | Maintains: Overweight | $355 → $350 | $315.64 | +10.89% | 16 | May 1, 2025 | |
| INCY Incyte | Maintains: Neutral | $70 → $68 | $64.93 | +4.73% | 6 | Apr 21, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Neutral | $55 → $58 | $54.43 | +6.56% | 12 | Apr 21, 2025 | |
| ONC BeiGene | Maintains: Overweight | $311 → $317 | $240.41 | +31.86% | 1 | Apr 21, 2025 | |
| IMCR Immunocore Holdings | Maintains: Overweight | $54 → $50 | $31.49 | +58.78% | 5 | Apr 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $29 → $28 | $19.38 | +44.52% | 4 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $47 → $45 | $32.43 | +38.76% | 4 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $280 → $328 | $285.81 | +14.76% | 5 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $200 → $209 | $107.01 | +95.31% | 4 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $83 → $92 | $66.36 | +38.64% | 7 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $24 | $13.04 | +84.05% | 5 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $110 → $109 | $58.09 | +87.64% | 3 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $32 → $26 | $29.90 | -13.04% | 6 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $12.59 | +138.28% | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $47 → $54 | $29.90 | +80.63% | 5 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $39 | $43.79 | -10.94% | 3 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $6 → $13 | $9.43 | +37.86% | 4 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $0.70 | - | 7 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $6.50 | - | 2 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | n/a | $0.83 | - | 9 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $11.29 | - | 6 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $65 → $76 | $28.29 | +168.65% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $1.73 | - | 2 | Aug 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $1.32 | +1,566.67% | 1 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $7 | $0.70 | +900.86% | 2 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $27 | $29.54 | -8.60% | 5 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $0.37 | - | 4 | Mar 11, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $6.92 | - | 3 | Feb 28, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $5.87 | - | 1 | Feb 8, 2018 |
Moderna
May 22, 2025
Maintains: Underweight
Price Target: $33 → $26
Current: $26.05
Upside: -0.19%
BioNTech SE
May 22, 2025
Maintains: Neutral
Price Target: $120 → $116
Current: $97.53
Upside: +18.94%
Vertex Pharmaceuticals
May 6, 2025
Maintains: Overweight
Price Target: $512 → $515
Current: $445.10
Upside: +15.70%
BioCryst Pharmaceuticals
May 6, 2025
Maintains: Overweight
Price Target: $10 → $13
Current: $10.56
Upside: +23.11%
Ascendis Pharma
May 2, 2025
Maintains: Overweight
Price Target: $200 → $245
Current: $159.41
Upside: +53.69%
United Therapeutics
May 1, 2025
Maintains: Overweight
Price Target: $355 → $350
Current: $315.64
Upside: +10.89%
Incyte
Apr 21, 2025
Maintains: Neutral
Price Target: $70 → $68
Current: $64.93
Upside: +4.73%
Halozyme Therapeutics
Apr 21, 2025
Maintains: Neutral
Price Target: $55 → $58
Current: $54.43
Upside: +6.56%
BeiGene
Apr 21, 2025
Maintains: Overweight
Price Target: $311 → $317
Current: $240.41
Upside: +31.86%
Immunocore Holdings
Apr 14, 2025
Maintains: Overweight
Price Target: $54 → $50
Current: $31.49
Upside: +58.78%
Apr 10, 2025
Maintains: Neutral
Price Target: $29 → $28
Current: $19.38
Upside: +44.52%
Mar 24, 2025
Maintains: Neutral
Price Target: $47 → $45
Current: $32.43
Upside: +38.76%
Mar 24, 2025
Upgrades: Overweight
Price Target: $280 → $328
Current: $285.81
Upside: +14.76%
Feb 26, 2025
Maintains: Overweight
Price Target: $200 → $209
Current: $107.01
Upside: +95.31%
Feb 7, 2025
Maintains: Overweight
Price Target: $83 → $92
Current: $66.36
Upside: +38.64%
Jan 7, 2025
Maintains: Overweight
Price Target: $28 → $24
Current: $13.04
Upside: +84.05%
Oct 30, 2024
Maintains: Overweight
Price Target: $110 → $109
Current: $58.09
Upside: +87.64%
Oct 25, 2024
Maintains: Neutral
Price Target: $32 → $26
Current: $29.90
Upside: -13.04%
Oct 8, 2024
Initiates: Overweight
Price Target: $30
Current: $12.59
Upside: +138.28%
Jul 9, 2024
Maintains: Overweight
Price Target: $47 → $54
Current: $29.90
Upside: +80.63%
Jun 18, 2024
Maintains: Overweight
Price Target: $31 → $39
Current: $43.79
Upside: -10.94%
Mar 26, 2024
Maintains: Neutral
Price Target: $6 → $13
Current: $9.43
Upside: +37.86%
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $0.70
Upside: -
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $6.50
Upside: -
Nov 20, 2023
Reinstates: Neutral
Price Target: n/a
Current: $0.83
Upside: -
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $11.29
Upside: -
Apr 19, 2023
Maintains: Overweight
Price Target: $65 → $76
Current: $28.29
Upside: +168.65%
Aug 20, 2021
Downgrades: Underweight
Price Target: n/a
Current: $1.73
Upside: -
Apr 19, 2021
Initiates: Overweight
Price Target: $22
Current: $1.32
Upside: +1,566.67%
Jan 29, 2021
Upgrades: Neutral
Price Target: $7
Current: $0.70
Upside: +900.86%
May 12, 2020
Maintains: Overweight
Price Target: $32 → $27
Current: $29.54
Upside: -8.60%
Mar 11, 2019
Downgrades: Underweight
Price Target: n/a
Current: $0.37
Upside: -
Feb 28, 2019
Downgrades: Underweight
Price Target: n/a
Current: $6.92
Upside: -
Feb 8, 2018
Downgrades: Neutral
Price Target: n/a
Current: $5.87
Upside: -